Investor Presentaiton
SELECT TRIALS - LEBRIKIZUMAB
Lilly
Study
Indication*
Title
Phase Patients
Primary Outcome*
**
Primary
Completion
Completion
NCT05369403
Atopic
Dermatitis
NCT05372419
A Study of Lebrikizumab (LY3650150) in Adult and
Adolescent Participants With Moderate-to-Severe Atopic
Dermatitis Previously Treated With Dupilumab (ADapt)
A Study of (LY3650150) Lebrikizumab to Assess the Safety
Atopic and Efficacy of Adult and Adolescent Participants With
Dermatitis Moderate-to-Severe Atopic Dermatitis and Skin of Color
(ADmirable)
3
120
Percentage of Participants Achieving Eczema Area and
Severity Index-75 (EASI-75) >75% Reduction in EASI Score
Oct 2023 Mar 2024
3
80
Percentage of Participants Achieving Eczema Area and
Severity Index-75 (EASI-75) (≥75% reduction from baseline Mar 2024 Aug 2024
in EASI)
NCT05559359
NCT04392154
Atopic
Dermatitis
Atopic
Dermatitis
A Study of Lebrikizumab (LY3650150) in Participants 6
Months to <18 Years of Age With Moderate-to-Severe
Atopic Dermatitis (ADorable-1)
Long-term Safety and Efficacy Study of Lebrikizumab
(LY3650150) in Participants With Moderate-to-Severe
Atopic Dermatitis (ADjoin)
3
300
Percentage of Participants Achieving Eczema Area and
Severity Index-75 (EASI-75) ≥75% Reduction from Baseline Aug 2024
in EASI Score
Jul 2025
3
1000
Percentage of Participants Discontinued from Study
Treatment due to Adverse Events through the Last
Treatment Visit
Sep 2024
Sep 2024
NCT05735483
A Study to Assess the Long-Term Safety and Efficacy of
Atopic Lebrikizumab (LY3650150) in Participants 6 Months to <18
Dermatitis Years of Age With Moderate-to-Severe Atopic Dermatitis
(ADorable-2)
3
250
Percentage of Participants Discontinued From Study
Treatment due to Adverse Events (AEs)
Nov 2025
Jun 2026
* Molecule may have multiple indications
** Trial may have additional primary and other secondary outcomes
Not for promotional use
Source: clinicaltrials.gov, July 24, 2023
2023 Q2 EARNINGS
41View entire presentation